Gene therapy RJK002 injected into spine for ALS – first human test begins
Disease control
Ongoing
This early-stage trial tests a single injection of RJK002, a gene therapy, into the spinal fluid of 9 people with ALS. The main goal is to see if it is safe and to find the best dose for future studies. Researchers will also track changes in daily function, but the trial is too s…
Phase: PHASE1 • Sponsor: RJK Biopharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC